Unison Advisors LLC Takes $3.68 Million Position in CVS Health Corporation (NYSE:CVS)

Unison Advisors LLC purchased a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 54,300 shares of the pharmacy operator's stock, valued at approximately $3,679,000.

Several other institutional investors and hedge funds also recently made changes to their positions in CVS. McIlrath & Eck LLC boosted its stake in CVS Health by 32.6% in the 4th quarter. McIlrath & Eck LLC now owns 707 shares of the pharmacy operator's stock worth $32,000 after purchasing an additional 174 shares during the period. Park Square Financial Group LLC purchased a new position in CVS Health during the 4th quarter valued at about $43,000. GW&K Investment Management LLC grew its holdings in CVS Health by 39.4% during the 1st quarter. GW&K Investment Management LLC now owns 637 shares of the pharmacy operator's stock valued at $43,000 after buying an additional 180 shares in the last quarter. PARK CIRCLE Co grew its holdings in CVS Health by 42.9% during the 4th quarter. PARK CIRCLE Co now owns 1,000 shares of the pharmacy operator's stock valued at $45,000 after buying an additional 300 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL grew its holdings in CVS Health by 77.2% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 1,024 shares of the pharmacy operator's stock valued at $46,000 after buying an additional 446 shares in the last quarter. Institutional investors own 80.66% of the company's stock.

CVS Health Price Performance

NYSE:CVS traded up $1.92 during mid-day trading on Friday, reaching $60.67. The stock had a trading volume of 10,876,795 shares, compared to its average volume of 6,441,933. The firm has a 50 day moving average price of $64.61 and a two-hundred day moving average price of $63.53. The stock has a market capitalization of $76.75 billion, a P/E ratio of 14.48, a P/E/G ratio of 0.87 and a beta of 0.57. CVS Health Corporation has a one year low of $43.56 and a one year high of $72.51. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. The business had revenue of $94.59 billion for the quarter, compared to analysts' expectations of $93.07 billion. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business's quarterly revenue was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm earned $1.31 EPS. As a group, analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, August 1st. Shareholders of record on Tuesday, July 22nd will be paid a $0.665 dividend. The ex-dividend date of this dividend is Tuesday, July 22nd. This represents a $2.66 dividend on an annualized basis and a yield of 4.38%. CVS Health's dividend payout ratio (DPR) is currently 63.48%.

Insider Buying and Selling

In related news, Director Guy P. Sansone purchased 1,570 shares of the firm's stock in a transaction on Thursday, June 5th. The shares were acquired at an average cost of $63.70 per share, with a total value of $100,009.00. Following the purchase, the director directly owned 12,007 shares of the company's stock, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 1.22% of the stock is owned by company insiders.

Analyst Ratings Changes

CVS has been the subject of a number of recent analyst reports. Truist Financial lifted their target price on CVS Health from $82.00 to $84.00 and gave the company a "buy" rating in a report on Monday, May 12th. Cowen reiterated a "buy" rating on shares of CVS Health in a research report on Monday, May 5th. Royal Bank Of Canada lifted their price target on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a research report on Monday, May 5th. UBS Group dropped their price target on CVS Health from $71.00 to $67.00 and set a "neutral" rating for the company in a research report on Tuesday, July 22nd. Finally, Wells Fargo & Company reiterated an "overweight" rating and set a $84.00 price target (up previously from $76.00) on shares of CVS Health in a research report on Tuesday, May 6th. Two equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $74.82.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.